Zynk | $5,000,000 | (Nov 5, 2025)
Downstream | $8,000,000 | (Nov 5, 2025)
Ruli | $6,000,000 | (Nov 5, 2025)
Certified by Founder
Lodge
Deverra Therapeutics
start up
United States
- Seattle
- 20/09/2023
- Unknown
- $2,400,000
Deverra Therapeutics is a clinical stage biotechnology company dedicated to the development of allogeneic, off-the-shelf cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. The company has an exclusive license to a proprietary stem cell expansion and directed-differentiation platform from the Fred Hutchinson Cancer Research Center based on more than 20 years of federally funded research and data from 5 clinical trials. This platform can be used to generate a range of unmodified and modified immune cells to treat patients with cancer and infectious diseases.
- Industry Biotechnology
- Website https://www.deverratx.com/
- LinkedIn https://www.linkedin.com/company/deverra-therapeutics/about/
Mine Vision Systems | $12,500,000 | (Nov 5, 2025)
Planbase (YC S24) | $2,100,000 | (Nov 5, 2025)
The EVERY Company | $55,000,000 | (Nov 5, 2025)
Daylight Security | $33,000,000 | (Nov 5, 2025)
Azalea Therapeutics | $82,000,000 | (Nov 5, 2025)
Parable | $11,000,000 | (Nov 5, 2025)
Beacon Software | $250,000,000 | (Nov 5, 2025)
Sunflower Labs | $16,000,000 | (Nov 5, 2025)
C.Scale | $2,000,000 | (Nov 5, 2025)
Portal26 | $9,000,000 | (Nov 5, 2025)